middle.news
Biotron Advances SedRxTM and Antiviral Programs After $1.52M Loss
1:21pm on Thursday 27th of August, 2026 AEST
•
Biotechnology
Read Story
Biotron Advances SedRxTM and Antiviral Programs After $1.52M Loss
1:21pm on Thursday 27th of August, 2026 AEST
Key Points
Net loss up 376.6% to $1.52 million
Completed Sedarex acquisition with $2.5 million capital raise
EMA feedback rules out Hybrid MAA for SedRxTM
Lead antiviral BIT-HBV001 shows activity against HBV and HDV
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Biotron (ASX:BIT)
OPEN ARTICLE